Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31539468 | 0.86 | FAAH (0.49) | MAPTTDP1FAAHNAAAMAPK1 | |
| SCHEMBL43877 | 0.82 | ALDH1A1 (0.51) | MAPTCA12CA1CA9 | |
| SCHEMBL18530063 | 0.81 | ALDH1A1 (0.50) | MAPTCA12CA1CA9 | |
| SCHEMBL14860981 | 0.80 | MAPK1 (0.48) | MAPTTDP1MAPK1 | |
| SCHEMBL4887726 | 0.76 | ERN1 (0.68) | DRD1TRIM24TRIM33ERN1CA12 | |
| SCHEMBL4872950 | 0.76 | SMN1; SMN2 (0.54) | MAPTMAPK1 | |
| SCHEMBL21160109 | 0.76 | MAPK1 (0.40) | TDP1FAAHMAPK1 | |
| SCHEMBL13455758 | 0.75 | SMN1; SMN2 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL27444665 | 0.75 | SMN1; SMN2 (0.50) | MAPTMAPK1 | |
| SCHEMBL4897945 | 0.75 | CA12 (0.46) | CA12CA1CA2CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045750-B2 | Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3 | MA YUELONG (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045750-B2 | Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3 | MA YUELONG (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130052731-A1 | HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 | MA YUELOG (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130052731-A1 | HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 | MA YUELOG (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052731-A1 | HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 | AGO2, HNRNPH3, HCLS1 | DRD1 1026/4885TRIM24 1951/4885TRIM33 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.